Announcements Trials
Browse Landscape

Phase

Phase 2 150Phase 1 50Phase 3 44Phase 1/2 37Phase 4 8Phase NA 5Phase 2/3 4Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Head and Neck Neoplasms 2Tonsillar Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pharyngeal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiosurgery 6pembrolizumab 4Carboplatin 3atezolizumab 2aldesleukin 2Paclitaxel 2Nivolumab 2Cyclophosphamide 2osimertinib 1durvalumab 1avelumab 1amatuximab 1Vitamin A 1Tobacco Use Cessation Devices 1Thoracic Surgical Procedures 1Taxes 1Radiotherapy 1Radiation Dose Hypofractionation 1RXDX-106 1Proton Therapy 1Pemetrexed 1Optical Fibers 1Oncolytic Virotherapy 1Itraconazole 1Interleukin-2 1Fluorodeoxyglucose F18 1Ethiodized Oil 1Erlotinib Hydrochloride 1Docetaxel 1Dihematoporphyrin Ether 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Non-Small-Cell Lung × Erlotinib Hydrochloride × Clear all
NCT02277457 2016-06-24

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡